Dr. Reddy's Laboratories Limited

Dr. Reddy's Announces Participation in Investor Conference

Dr. Reddy's Laboratories Limited announced that the company’s management will participate in an investor conference organized by Bank of America in Singapore on 8-9 December 2025.

Dr. Reddy's Announces Participation in Investor Conference

Dr. Reddy's Laboratories Limited will participate in Nomura's investor conference in Tokyo, Japan, on December 4-5, 2025, for in-person group meetings. The schedule is subject to change.

Aurigene Oncology Receives Order from GST Appellate Authority

Aurigene Oncology, a Dr. Reddy's subsidiary, received an order from GST Appellate Authority regarding tax demand. The order levies a penalty of ₹3,46,998. Dr. Reddy's will evaluate filing an appeal.

Aurigene Oncology receives order from GST Appellate Authority

Aurigene Oncology, a subsidiary of Dr. Reddy's, received an order from the GST Appellate Authority with a penalty of ₹64.95 lakh. The company is evaluating further appeals.

Dr. Reddy's Receives EC Approval for AVT03, Biosimilar of Prolia® and Xgeva®

Dr. Reddy's Laboratories receives European Commission approval for AVT03, a biosimilar of Prolia® and Xgeva®. This follows a partnership with Alvotech for development and commercialization.

Dr. Reddy's to Participate in Investor Conferences in November 2025

Dr. Reddy's Laboratories Limited will participate in investor conferences organized by Investec and Citi in November 2025.

Dr. Reddy's announces special window for re-lodgement of physical share transfer requests

Dr. Reddy's published notices on lost share certificates and opened a special window until January 6, 2026, for re-lodging physical share transfer requests rejected earlier.

Dr. Reddy's Laboratories to participate in JM Financial Investor Conference on November 21, 2025

Dr. Reddy's management will attend an investor conference organized by JM Financial on November 21, 2025, in Mumbai for an in-person group meet.

Dr. Reddy's Srikakulam API facility receives zero USFDA observations

Dr. Reddy's Srikakulam API facility passed a USFDA GMP inspection with zero observations from November 10-14, 2025, indicating strong compliance with manufacturing standards.

Dr. Reddy's Allots 7,430 Equity Shares Under ESOP Scheme

Dr. Reddy's allotted 7,430 equity shares on November 13, 2025, to employees exercising stock options under its 2002 ESOP Scheme, increasing total issued shares to 83,46,22,190.

Dr. Reddy's clarifies cyber fraud report; no financial loss incurred

Dr. Reddy's clarified a media report about a ₹2.16 crore cyber fraud attempt, confirming no financial loss to the company or vendor due to timely intervention and frozen funds.

Mr. Jayanth Sridhar Resigns as Global Head of Biologics

Mr. Jayanth Sridhar has resigned from the position of Global Head of Biologics of Dr. Reddy's Laboratories Limited, effective January 31, 2026.

Dr. Reddy's Laboratories publishes notice regarding loss of share certificates

Dr. Reddy's Laboratories published a notice on November 5, 2025, regarding lost share certificates. Claims must be lodged within 15 days, after which duplicate certificates will be issued to shareholders.

Dr. Reddy's Q2FY26 Earnings Call Transcript

Dr. Reddy's Q2FY26 results: Revenue ₹8,805 crore, up 9.8% YoY; PAT ₹1,437 crore, up 14% YoY. Awaiting court decision on Semaglutide patent challenge in India. BLA submission for Abatacept expected by Dec 2025.

Dr. Reddy's receives Non-Compliance Notice from Canada for Semaglutide Injection ANDS

Dr. Reddy's received a Notice of Non-Compliance from Canada for its Semaglutide Injection submission, requiring additional information. The company will respond, confident in its product.

Dr. Reddy's announces publication of Q2 and H1 FY26 unaudited financial results

Dr. Reddy's announced the newspaper publication of its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, following board approval on October 24, 2025.

Dr. Reddy's provides audio recording of Q2 FY26 earnings call

Dr. Reddy's Laboratories Limited provides the audio recording of its earnings call held on October 24, 2025, for the quarter ended September 30, 2025, via a web link.

Dr. Reddy's Appoints Sanjay Sharma as Additional CHRO

Dr. Reddy's appoints Sanjay Sharma as additional CHRO effective December 1, 2025, following Archana Bhaskar's resignation effective November 30, 2025. The decision was made on October 24, 2025.

Dr. Reddy's Reports Near Double-Digit Revenue Growth, Steady Profitability in Q2 FY26, Releases Investor Presentation

Dr. Reddy's reported Q2 FY26 revenues of ₹ 8,805 crore and PAT of ₹ 1,437 crore, with near double-digit growth. Strategic acquisitions and new product launches drove performance, alongside progress in ESG and pipeline development.

Dr. Reddy's Reports Q2 & H1 FY26 Results: Revenues Up, PAT Rises Amidst Strategic Growth

Dr. Reddy's reports Q2 & H1 FY26 consolidated revenues up 9.8% and 10.6% YoY, respectively. PAT grew 14% and 8% YoY. Strategic acquisitions and new product launches drive growth despite North America challenges.

Dr. Reddy's receives 'Voluntary Action Indicated' from USFDA for Srikakulam facility

Dr. Reddy's received a 'Voluntary Action Indicated' (VAI) classification from the USFDA for its Srikakulam facility inspection, closing the matter without regulatory action.

Dr. Reddy's to Release Q2FY26 Results and Host Earnings Call on Oct 24, 2025

Dr. Reddy's will release its Q2FY26 results on October 24, 2025, followed by an earnings call at 19:30 PM IST to discuss the financial performance. Presentation and call details will be on the company website.

Dr. Reddy's Announces Special Window for Physical Share Transfer Re-lodgment

Dr. Reddy's announces a special window from July 7, 2025, to January 6, 2026, for re-lodgment of physical share transfer requests as per SEBI guidelines.

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Dr. Reddy's Announces Special Window for Physical Share Re-lodgement

Promoters transfer 20.58% shares to family trusts via off-market transfer.

Dr. Reddy's launches novel molecule ‘Tegoprazan’ in India

DRREDDY Allots 6,475 Equity Shares Under ESOP Scheme

Dr. Reddy's receives 5 USFDA observations for Bachupally biologics facility PAI

Dr. Reddy's to acquire STUGERON® portfolio from Janssen for $50.5 million

Dr. Reddy's API Mirfield facility receives 7 USFDA observations during GMP inspection

Dr. Reddy's Announces Special Window for Physical Share Transfer Re-lodgement

Dr. Reddy's Receives Penalty Order from GST Authority

Ms. Archana Bhaskar Resigns as CHRO of Dr. Reddy's Laboratories

Dr. Reddy's Receives Interim Stay on Income Tax Reassessment Notice

Dr. Reddy's Announces Special Window for Physical Share Transfer Re-lodgement

Dr. Reddy's Laboratories to participate in Nirmal Bang virtual investor meet

Dr. Reddy's Q1 FY26 Revenues Up 11% YoY Amidst US Generics Decline; Strategic Pipeline Progress

Dr. Reddy's invests ₹565.41 crore in its Russian subsidiary, DRL Russia

Dr. Reddy's Appoints Makarand M Joshi & Co as Secretarial Auditors

Shareholders Approve Re-appointment of G V Prasad as Co-Chairman & MD

Dr. Reddy's Laboratories' 41st AGM Approves Financials, ₹8 Dividend, and Director Re-appointments

Dr. Reddy's Laboratories Publishes Q1 FY26 Unaudited Financial Results Advertisement

Dr. Reddy's intends to appoint Deloitte as Statutory Auditors from FY 2026-27

Dr. Reddy's Reports Double-Digit Revenue Growth and Steady Profitability in Q1 FY26

Dr. Reddy's Reports 11% YoY Revenue Growth for Q1 FY26; Profit Up 2%

Dr. Reddy's USFDA Inspection at New York API Facility Concludes with VAI Classification